Skip to content
OpenCapital
Get started

Bausch + Lomb BLCO Free cash flow

Free cash flow at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$1.47B-56.6%
AbbVie logo
AbbVieABBV
$3.56B+155%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$848.3M+4.0%
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
——
Glaukos logo
GlaukosGKOS
——
Solventum logo
SolventumSOLV
——

Other financials

Income statement

See full
Revenue$1.2B+9.4%
Operating income$33.0M+140%
Net income-$71.0M+66.5%
EPS (diluted)-$0.20+66.7%

Balance sheet

See full
Cash & equivalents$279.0M+29.8%
Total debt$5.0B+4.3%
Total equity$6.4B+0.3%
Total assets$13.8B+2.6%

Cash flow

See full
Operating cash flow$32.0M+228%
CapEx$100.0M-9.1%

Valuation

See full
Market cap$5.3B+10.2%
Enterprise value$10.06B+6.9%
P/S1×0.0×

Profitability

See full
Operating margin4.4%+2.9pp
Net margin-4.2%-1.3pp
FCF margin-3.4%0.0pp

Returns & leverage

See full
Return on equity-3.4%-0.9pp
Debt / equity0.8×0.0×
Current ratio1.5×0.0×

Where this comes from

Calculated from Bausch + Lomb’s reported figures.

$32.0Mnet cash from operating−$100.0Mcapital expenditures=-$68M

The official record: Bausch + Lomb’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bausch + Lomb's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bausch + Lomb's free cash flow?
Bausch + Lomb (BLCO) reported free cash flow of -$68M in Q1 2026.
How has Bausch + Lomb's free cash flow changed year-over-year?
Bausch + Lomb's free cash flow increased by 49.6% year-over-year, from -$135M to -$68M.
What is the long-term trend for Bausch + Lomb's free cash flow?
Over 2 years (2021 to 2024), Bausch + Lomb's free cash flow has grown at a -70.5% compound annual growth rate (CAGR), from $680M to -$59M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.